Wu Zhong-Hui, Xia Hai-Long
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China.
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Dec;25(6):1702-1706. doi: 10.7534/j.issn.1009-2137.2017.06.022.
To study the significance of detecting the plasma level of matrix metalloproteinase-13(MMP-13) in patients with multiple myeloma(MM) and to investigate the correlation of MMP-13 levels in MM patients with myeloma bone disease(MBD).
The plasma level of MMP-13 was quantitatively analyzed in 53 newly diagnosed MM patients and 30 healthy controls by enzyme-linked immunosorbent assay(ELISA). Imaging examination was used to determine bone damage in patients with MM. At the same time, using a dual-energy X-ray absortionmetry(DXA), the bone mineral density was examined on vertebra L2 to L4 in the anteroposterior position and the proximal left femur in 17 MM patients and 15 healthy controls.
The plasma level of MMP-13 in MM patients was significantly higher than that in the controls(P<0.01), and the MMP-13 level in MM patients with stage III of International Staging System(ISS) was significantly higher than that in patients with stage I-II(P<0.01). The MMP-13 level in MM patients without MBD was significantly higher than that in the controls(P<0.05). According to bone disease grading, 53 patients were divided into group A(bone grade 0-2, n=18)and group B(bone grade 3-4, n=35). Compared with group A, MMP-13 level group B was enhanced significantly (P<0.01). Further analyses revealed that the level of MMP-13 negatively correlated with the bone mineral density on L2 to L4, greater trochanter and Ward's triangle(r values were -0.693, -0.575 and -0.575, respectively, P<0.05), but not correlated with left femoral neck(r= -0.339)(P>0.05).
The level of MMP-13 in MM patients is significantly high, and closely relates with ISS clinical stage, degree of MBD and the bone mineral density of MM patients. MMP-13 plays an important role in the development of MBD.
研究检测多发性骨髓瘤(MM)患者血浆基质金属蛋白酶-13(MMP-13)水平的意义,并探讨MM患者MMP-13水平与骨髓瘤骨病(MBD)的相关性。
采用酶联免疫吸附测定(ELISA)法对53例新诊断的MM患者和30例健康对照者的血浆MMP-13水平进行定量分析。采用影像学检查确定MM患者的骨损伤情况。同时,对17例MM患者和15例健康对照者采用双能X线吸收法(DXA)检测第2至4腰椎前后位及左侧股骨近端的骨密度。
MM患者血浆MMP-13水平显著高于对照组(P<0.01),国际分期系统(ISS)III期MM患者的MMP-13水平显著高于I-II期患者(P<0.01)。无MBD的MM患者MMP-13水平显著高于对照组(P<0.05)。根据骨病分级,将53例患者分为A组(骨分级0-2级,n=18)和B组(骨分级3-4级,n=35)。与A组相比,B组MMP-13水平显著升高(P<0.01)。进一步分析显示,MMP-13水平与第2至4腰椎、大转子和Ward三角区的骨密度呈负相关(r值分别为-0.693、-0.575和-0.575,P<0.05),但与左侧股骨颈无相关性(r=-0.339)(P>0.05)。
MM患者MMP-13水平显著升高,且与ISS临床分期、MBD程度及MM患者的骨密度密切相关。MMP-13在MBD的发生发展中起重要作用。